[1/2] Test tubes are seen in front of a displayed Biontech logo in this illustration taken, May 21, 2021.
REUTERS/Dado Ruvic/IllustrationNov 14 (Reuters) - BioNTech SE (22UAy.DE), the German biotech that developed a widely used COVID-19 vaccine with Pfizer Inc (PFE.N), acquired a manufacturing facility in Singapore, its first in Asia, the company said on Monday.
The facility, bought from a Novartis (NOVN.S) unit, will be its first messenger ribonucleic acid, or mRNA, facility in Singapore and support its vaccines production for the Asia Pacific region, BioNTech said in a statement, without disclosing financial details.
The aim is to eventually expand production to other drug classes such as cell therapies, said BioNTech, which also plans to set up research and manufacturing centres in Australia.
The Singapore facility is expected to be fully operational by 2023 and create more than 100 jobs by 2024.